Baker Bros. Advisors Lp Insider Profile
228 Followers
Baker Bros. Advisors Lp, Director, Ten Percent Owner at Replimune Group, holds ― shares in Replimune Group (Ticker: REPL), holds 4.37M shares in Celcuity (Ticker: CELC), holds 28.80M shares in Incyte (Ticker: INCY). Most recently, Baker Bros. Advisors Lp ― shares of Replimune Group on ― for an estimated value of ―.
Baker Bros. Advisors Lp Replimune Group (REPL)Director, Ten Percent Owner
Replimune Group (REPL)
Director, Ten Percent Owner
Ranked #220 out of 109,349 Corporate Insiders
Profitable Transactions
56 out of 102 Profitable Transactions
Average Return
+29.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Baker Bros. Advisors Lp's holdings
Insider Roles
Roles that Baker Bros. Advisors Lp holds in companies
Most Profitable Insider Trade
Stock:
Invitae
(NVTAQ)
(NVTAQ)
Rating:Informative Buy
Date:Mar 29, 2018 - Mar 29, 2019
Return:+399.30%
The most profitable trade made by Baker Bros. Advisors Lp
Baker Bros. Advisors Lp's Trading History
Replimune Group
―
Director, Ten Percent Owner
―
―
Denali Therapeutics
Jun 05, 2026
Director
Uninformative Buy
―
$66.12M
Celcuity
Jul 16, 2026
Former 10% owner
Informative Sell
317.75M
$303.04M
BioCryst
Aug 16, 2016
Ten Percent Owner
Informative Sell
20.25M
$128.34M
Bellicum Pharmaceuticals
Nov 24, 2023
―
Uninformative Buy
―
$160.49K
BeOne Medicines
Jun 15, 2026
Director
Uninformative Buy
―
$3.34B
Aceragen
Jul 03, 2019
―
Uninformative Buy
15.47K
$1.65M
Alexion Pharmaceuticals
May 18, 2020
―
Uninformative Buy
―
$1.47B
Kiniksa Pharmaceuticals
Jun 02, 2026
Director
Uninformative Buy
―
$270.69M
Hookipa Pharma
Apr 23, 2019
―
Informative Buy
12.50M
$943.84K
Kodiak Sciences
Dec 19, 2025
Director, Ten Percent Owner
Informative Buy
60.00M
$1.84B
IGM Biosciences
Aug 18, 2025
―
Uninformative Sell
―
$0.00
Atreca
Oct 23, 2023
―
Informative Sell
109.90K
$267.40K
Zymeworks
―
Director
―
―
Prelude Therapeutics
Jan 29, 2021
Director, Ten Percent Owner
Uninformative Buy
133.33K
$37.94M
Spyre Therapeutics
―
Director
―
―
Talis Biomedical
Nov 19, 2021
―
Informative Buy
218.00K
$21.66M
TScan Therapeutics
May 12, 2022
Director
Informative Buy
2.56M
$490.55K
Entrada Therapeutics Inc
Nov 24, 2025
Ten Percent Owner
Informative Buy
261.68K
$20.64M
DBV Technologies SA - American
Jun 13, 2022
Director
Uninformative Buy
―
$300.37M
Madrigal Pharmaceuticals
Jun 18, 2026
Director
Uninformative Buy
―
$841.33M
vTv Therapeutics
Sep 05, 2025
Director
Uninformative Buy
―
$3.59M
Kymera Therapeutics
Dec 11, 2025
Director, Ten Percent Owner
Informative Buy
172.50M
$975.40M
Bicycle Therapeutics
Jan 06, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$38.27M
Immunocore Holdings
Mar 19, 2025
Director
Informative Buy
23.99M
$67.04M
KALA BIO
Oct 02, 2025
Former 10% owner
Informative Sell
1.05M
$74.38K
Mirati Therapeutics
Nov 13, 2017
―
Informative Buy
2.20M
$2.13M
Neurogene
Oct 10, 2023
Director, Former 10% Owner
Uninformative Buy
―
$13.08M
Invitae
Mar 29, 2018
―
Informative Buy
5.00M
$83.09K
ACADIA Pharmaceuticals
Jun 02, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$821.90M
XOMA Royalty Corporation
Jul 23, 2015
―
Informative Sell
11.99M
$3.64M
Genomic Health
Oct 03, 2019
―
Uninformative Buy
124.47K
$484.81M
Incyte
Jul 02, 2026
Director, Ten Percent Owner
Uninformative Buy
―
$3.36B
Seagen
Jun 02, 2023
―
Uninformative Buy
―
$9.84B
Synageva
―
―
―
―
List of latest transactions for each holding click on a transaction to see Baker Bros. Advisors Lp's performance on stock
You May Also Like
Baker Bros. Advisors Lp insider profile FAQ
What is the percentage of profitable transactions made by Baker Bros. Advisors Lp?
The percentage of profitable transactions made by Baker Bros. Advisors Lp is 55%.
What is the average return per transaction made by Baker Bros. Advisors Lp?
The average return per transaction made by Baker Bros. Advisors Lp is 29.20%.
What stocks does Baker Bros. Advisors Lp hold?
Baker Bros. Advisors Lp holds: REPL, DNLI, CELC, BCRX, BLCM, ONC, ACGN, ALXN, KNSA, HOOK, KOD, IGMS, BCEL, ZYME, PRLD, SYRE, TLIS, TCRX, TRDA, DBVT, MDGL, VTVT, KYMR, BCYC, IMCR, KALA, MRTX, NGNE, NVTAQ, ACAD, XOMA, GHDX, INCY, SGEN, GEVA stocks.
What was Baker Bros. Advisors Lp’s latest transaction?
Baker Bros. Advisors Lp latest transaction was an Uninformative Buy of ―.
What was Baker Bros. Advisors Lp's most profitable transaction?
Baker Bros. Advisors Lp’s most profitable transaction was an Informative Buy of NVTAQ stock on March 29, 2018. The return on the trade was 399.30%.
What is Baker Bros. Advisors Lp's role in Replimune Group?
Baker Bros. Advisors Lp's role in Replimune Group is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.